Pharmacy & Drug Pricing
Expert articles and analysis related to pharmacy & drug pricing.
AI Summary — Last 24 Hours
FDA warning letters to 25 telehealth companies marketing compounded GLP-1s intensify pressure on employers, plans, and risk-bearing providers to tighten obesity-drug coverage, utilization management, and safety monitoring as demand keeps rising and coverage decisions remain unsettled. For VBC stakeholders, the near-term issue is less whether GLP-1s “work” and more how to operationalize appropriate prescribing, affordability, and adherence across pharmacy workflows, especially as prescription price transparency remains a point-of-care workflow problem rather than simply a data problem. Medicaid and ACO leaders should also watch biosimilar adoption barriers, hospital specialty pharmacy growth, and payment-arrangement incentives, which continue to shape total cost of care and drug-spend accountability in population-based models (FDA GLP-1 warning letters; Drug Channels roundup).
Related Articles
Why Pharmacists Are Central to Closing Care Gaps in the New CKM Syndrome Guideline
Readers Write: Prescription Price Transparency Is a Workflow Problem, Not Just a Data Problem
Prescription Price Transparency Is a Workflow Problem, Not Just a ...
Will employers still cover GLP-1s for weight loss?
Q&A: PBMs Use Audits to Generate Revenue Amid Unprecedented Scrutiny
A Troubling Trend from a Pharmaceutical Giant
A Troubling Trend from a Pharmaceutical Giant RACmonitor
FDA warns telehealth companies over compounded GLP-1s
The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims in their marketing of compounded GLP-1 weight loss drugs. The letter...
FDA Clears Second Over-the-Counter Naloxone Spray to Fight Opioid Overdose Crisis
UK waitlist for Novo's Wegovy pill triples in week after approval, major online pharmacy says
The waiting list at a UK online pharmacy for Novo Nordisk’s Wegovy pill now stands at 30,000 people a week after approval, in a sign of dramatic demand for the weight loss drug among patients ...